TechnologymRNA Cancer Vaccine Cuts Melanoma Recurrence by 49% After Five Years
New five-year data from the KEYNOTE-942 trial shows Moderna's personalized mRNA vaccine intismeran, paired with Keytruda, nearly halves the risk of melanoma returning after surgery.
